Millennium Predictive's Outcome
Executive SummaryMillennium Pharmaceuticals' new collaboration with Roche Diagnostics to develop prognostic and therapeutic information products in rheumatoid arthritis is notable as being only the second molecular diagnostics discovery deal involving the delivery of targets to a large diagnostics company (the first being Millennium's Becton Dickinson deal in cancer). But the news behind the scenes is that Millennium has also quietly re-integrated two of the three programs in its Predictive Medicine subsidiary, setting the stage for the roll-out of a major, web-based personalized medical information play, most likely by year-end.
You may also be interested in...
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.